CXCR2 and chronic obstructive pulmonary disease: Enhanced NET induction in autologous blood and sputum neutrophils from COPD patients, this response was stabilized using the CXCR2 antagonist, AZD5069. This is the first mechanistic study to show an association specifically between CXCR2 signaling and NET stabilization in COPD ex vivo (Figures 1B–D)